Tretinoin 0.1% cream is indicated for the treatment of pregnancy-related abdominal striae (stretch marks). It is also indicated for the topical treatment of acne vulgaris, mottled hyperpigmentation, photodamaged skin, flat warts, and other skin conditions such as ichthyosis vulgaris and keratosis follicularis.

Tretinoin 0.025% cream is indicated for topical application in the treatment of acne vulgaris in which comedones, papules, and pustules predominate.

Although the exact mode of action of Tretinoin is unknown, current evidence suggests that topical Tretinoin decreases the cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, Tretinoin stimulates mitotic activity and increases the turnover of follicular epithelial cells, causing extrusion of the comedones, papules, and pustules.

This cream should be applied sparingly to the whole affected area once or twice daily. The skin should be thoroughly cleaned and dried before application. Patient should be advised that 6 to 8 weeks of treatment may be required before a therapeutic effect is observed. Moisturizers and cosmetics may be used during treatment with Tretinoin cream but should not be applied to the skin at the same time. Astringent toiletries should be avoided.

Other topical acne treatments should be used with caution during treatment with Tretinoin. Particular caution should be exercised when using a preparation containing a peeling agent, for example, benzoyl peroxide. It is also possible to apply Tretinoin and benzoyl peroxide alternately. The suggested regimens are either Tretinoin in the morning and benzoyl peroxide in the evening, or the preparations should be used on alternate days.

Tretinoin is contraindicated in those who are highly sensitive to any of the ingredients. This cream should not be used in patients with a personal or family history of cutaneous epithelioma (skin cancer).

Initial external application of Tretinoin generally may cause burning or slight irritation. Erythema and peeling at the site of application may also occur. If irritation becomes severe and persists, discontinue application and consult your physician if necessary.

There is inadequate evidence of the safety of topically applied Tretinoin in human pregnancy. Tretinoin has been associated with teratogenicity in humans when administered systemically. Therefore, the cream should not be used during pregnancy and lactation.

Avoid contact of Tretinoin with the lips, mouth, eyes, eyelids, nostrils, or other mucous membranes. If contact with these areas occurs, careful washing with water is recommended. Apply the cream to sensitive areas of skin, such as the neck, with caution. Do not use it on broken, eczematous, or sunburned skin.

Topical retinoid and related preparations

Keep out of the reach of children. Keep in a cool and dry place, protected from light.